**SUPPLEMENTARY MATERIALS**

**S1. File.** Invitation letters sent to index and cascade screening participants

**S1.1. File.** Invitation letter sent to index participant

**S1.2. File.** Invitation letter sent to cascade screening participants

**S2. Table.** Information on deceased individuals

**S3. Table.** Characteristics of cascade screening participants

**S4. Table.** Individual responses to surveys administered immediately and 6 months after disclosure of genetic risk information

**S5. Table.** Breast cancer population screening vs. identification of high-risk individuals: criteria for further risk evaluation

**File S1.** **Invitation letters sent to index and cascade screening participants.**

The original documents, approved by the Research Ethics Committee of the University of Tartu, have been translated from Estonian to English for reference purposes.

**S1.1. Invitation letter sent to index participants**

**Dear biobank participant,**

Thank you for your contribution to the creation of the database of the Estonian Genome Center of the University of Tartu.

In terms of its quality and volume, the database is now a representative and reliable source for the development of medical science both in Estonia and worldwide. In recent years, we have focused primarily on research, and the first study groups can now be given personal feedback based on the results of the genetic analysis.

The Estonian Genome Center has undertaken a research study involving biobank participants selected on the basis of genome-wide analysis. You have been selected to participate in this study. The main purposes of the study are to investigate the impacts of hereditary factors on health risks and provide personalized recommendations for prevention, treatment options and follow-up tactics, where appropriate.

The appointments scheduled for the study will be held at the Estonian Genome Center of the University of Tartu. You will be interviewed and examined by a medical geneticist and an additional blood sample (up to 50 ml of venous blood) will be collected from you for further genetic and laboratory tests.

Upon request, all participants will have the opportunity to obtain personal feedback on their genetic data from a medical geneticist, genetic counselor or clinical genomics specialist, depending on the nature of the results.

**Please let us know if you are interested in participating in this study**

by calling the Genome Center at 737 4030 or 5345 5481 (from 9 a.m. to 4 p.m. on weekdays),

by sending an SMS or by emailing us at tkinfo@geenivaramu.ee.

To ensure that the appointments run smoothly, we would be grateful if you could notify us of your wish to participate in the study up to one month after receiving this letter. If we do not receive any response from you within this time, we will send you another letter. If we do not receive any response to the repeated letter, we will contact you by telephone.

An appointment will be booked for you. During the first visit, the nature of the study will be explained to you. You can ask questions to decide whether or not you want to participate in the study. After the relevant written consent has been obtained, some questionnaires will be completed and a blood sample will be taken. You are expected to attend two study visits, which can last from three to four hours in total. The transport costs associated with the visits will be reimbursed on the basis of the travel documents submitted by you.

I wish you all the best and thank you for your cooperation with the Estonian Genome Center of the University of Tartu!

Prof. Andres Metspalu

Director of the Estonian Genome Center of the University of Tartu

**S1.2. Invitation letter sent to cascade screening participants**

**Information for close relatives of study participants with gene variants requiring medical intervention**

We are writing to you because your close relative is participating in a research study which aims to provide feedback on medically important hereditary genetic risk factors in the family. Knowing about these risk factors can be important for early detection of diseases and for making lifestyle choices. With timely medical intervention, the risk of complications is significantly reduced and informing close relatives is considered justified and necessary.

**We invite you to participate in the same study** to identify the genetic variants associated with hereditary health risks in your family. Participating in the study can provide important information for you and your other close relatives. The study is carried out by researchers of the Estonian Genome Center of the University of Tartu. We collaborate with Tartu University Hospital and the North Estonia Medical Center.

**What participation in the study would mean for you**

The appointments scheduled for the study will be held at the Estonian Genome Center of the University of Tartu. An appointment will be booked for you. During the visit, the nature of the study will be explained to you. You can ask questions to decide whether or not you want to participate in the study. After the relevant written consent has been obtained, the health information for you and your close relatives will be discussed, you will undergo a general medical examination and blood samples for DNA and other tests will be collected. To map possible abnormalities more accurately, your blood samples may be used, for example, for RNA, biochemical and metabolic analysis. If you are found to have a hereditary health risk, you will be advised to consult a specialist. You are expected to attend up to two study visits, which can last from three to four hours in total.

**Reimbursement for study-related costs**

The transport costs associated with the visits will be reimbursed on the basis of the travel documents submitted by you. You do not have to pay for the study analysis yourself.

**Please let us know if you are interested in participating in this study**

by calling the Genome Center at 737 4030 or 5345 5481 (from 9 a.m. to 4 p.m. on weekdays),

by sending an SMS or by emailing us at tkinfo@geenivaramu.ee.

**Thank you for reading this information.**

**I wish you good health and all the best for the future!**

Prof. Andres Metspalu

Director of the Estonian Genome Center of the University of Tartu

**Table S2. Information on deceased individuals**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **ID** | **Sex** | **Age at death** | **Cause of death (ICD-10 Code)1** | **rsID** | **Gene** |
| Deceased 1 | F | <50 | C50.9 Malignant neoplasm of breast of unspecified site | novel | BRCA1 |
| Deceased 2 | M | >80 | C34.9 Malignant neoplasm of unspecified part of bronchus or lung | rs80357906 | BRCA1 |
| I25.9 Chronic ischemic heart disease, unspecified |
| Deceased 3 | M | >70 | C22.1 Intrahepatic bile duct carcinoma | rs80357906 | BRCA1 |
| Deceased 4 | M | <45 | C15.9 Malignant neoplasm of esophagus, unspecified | rs80359112 | BRCA2 |

1As noted on death certificates, data from the Estonian Causes of Death Registry.

**Table S3. Characteristics of cascade screening participants**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **ID1** | **Relation to index** | **Age range** | **Sex** | **Children** | **Ca.dx. and age range at dx.** | **Family history of cancer** | **Carrier of LP/KP variant** |
| 1.2 | 1st degree relative | 25-29 | M | 0 | no | high | yes |
| 1.1 | 2nd degree relative | 60-64 | F | 3 | cervical ca., 40-44 | high | no |
| 1.3 | 1st degree relative | 35-39 | F | 0 | no | high | no |
| 2.1 | 1st degree relative | 75-79 | F | 1 | BC, 45-49 | moderate | yes |
| 2.2 | 1st degree relative | 18-24 | M | 0 | no | moderate | yes |
| 4.2 | 1st degree relative | 25-29 | F | 0 | no | moderate | yes |
| 4.1 | 2nd degree relative | 40-44 | F | 0 | no | moderate | no |
| 5.2 | 1st degree relative | 35-39 | F | 3 | no | high | yes |
| 5.1 | 2nd degree relative | 60-64 | M | 3 | no | high | no |
| 5.3 | 1st degree relative | 20-24 | F | 0 | no | high | no |
| 5.4 | 1st degree relative | 25-29 | M | 0 | no | high | no |
| 7.3 | 1st degree relative | 30-34 | M | 0 | no | low | yes |
| 7.4 | 1st degree relative | 30-34 | M | 1 | no | low | yes |
| 7.1 | 2nd degree relative | 30-34 | M | 0 | no | low | no |
| 7.2 | 1st degree relative | 60-64 | M | 2 | no | low | no |
| 7.5 | 2nd degree relative | 35-39 | F | 2 | melanoma, 30-34 | low | no |
| 9.1 | 2nd degree relative | 45-49 | F | 3 | no | moderate | no |
| 9.2 | 2nd degree relative | 50-54 | M | 0 | no | moderate | no |
| 9.3 | 2nd degree relative | 50-54 | M | 3 | no | moderate | no |
| 10.1 | 1st degree relative | 55-59 | F | 3 | BC, 35-39 | high | yes |
| 12.1 | 1st degree relative | 18-24 | F | 0 | no | high | yes |
| 17.2 | 1st degree relative | 30-34 | F | 2 | no | moderate | yes |
| 17.1 | 1st degree relative | 30-34 | M | 2 | no | moderate | no |
| 17.3 | 1st degree relative | 30-34 | M | 0 | no | moderate | no |
| 17.4 | 2nd degree relative | 55-59 | F | 0 | no | moderate | no |
| 20.1 | 1st degree relative | 40-44 | M | 2 | no | low | no |

BC, breast cancer; LP, likely pathogenic; KP, known pathogenic.

1The first digit is the ID number of the index individual and the second digit is the number of the relative who underwent cascade screening.

**Table S4. Individual responses to surveys administered immediately and 6 months after disclosure of genetic risk information**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Participant ID** | **1** | **2** | **3** | **4** | **5** | **6** | **7** | **8** | **9** | **10** | **11** | **12** | **13** | **14** | **15** | **16** | **17** | **18** | **20** | **21** | **22** | **Mean** |
| **Immediate response** | **Emotional Response**1 | | | | | | | | | | | | | | | | | | | | | | |
| I feel calm | 4 | 4 | 2 | 3 | 4 | 4 | 3 | 3 | 1 | 3 | 4 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 4 | 3 | 3 | 3.3 |
| I am tense | 2 | 3 | 2 | 1 | 1 | 1 | 2 | 3 | 4 | 2 | / | 1 | 1 | 1 | 3 | 2 | 1 | 2 | 1 | 1 | 2 | 1.8 |
| I feel upset | 2 | 1 | 2 | 1 | 2 | 2 | 2 | 2 | 4 | 2 | / | 1 | 2 | 1 | 2 | 2 | 2 | 2 | 1 | 1 | 2 | 1.8 |
| I am relaxed | 4 | 1 | 4 | 4 | 4 | 3 | 4 | 4 | 2 | 3 | 4 | 4 | 3 | 4 | 3 | 3 | 4 | 4 | 4 | 3 | 4 | 3.5 |
| I feel content | 2 | 4 | 4 | 3 | 4 | 4 | 1 | 3 | 2 | 4 | 4 | 4 | 3 | 4 | 3 | 3 | 3 | 4 | 3 | 4 | 3 | 3.3 |
| I am worried | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 4 | 2 | / | 2 | 2 | 1 | 2 | 2 | 2 | 3 | 2 | 2 | 2 | 2.2 |
| **Perceived impact**2 | | | | | | | | | | | | | | | | | | | | | | |
| Information provided was understandable | 4 | 5 | 4 | 5 | 5 | 5 | 5 | / | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 4.9 |
| Information provided was interesting | 5 | 5 | 4 | 5 | 4 | 5 | 4 | 5 | 5 | 5 | 5 | 4 | 3 | 5 | 5 | 5 | 5 | 5 | 5 | 4 | 5 | 4.7 |
| Information provided was informative | 5 | 5 | 4 | 5 | 5 | 5 | 4 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 4.9 |
| Information provided was valuable | 5 | 5 | 4 | 5 | 5 | 5 | 5 | 4 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 4.9 |
| I understand the potential impact of the finding on my close relatives | 5 | 5 | 4 | 5 | 5 | 5 | 5 | 4 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 4 | 5 | 5 | 5 | 4.9 |
| I can explain the potential impact of this genetic finding on health risks to my family members | 5 | 5 | 4 | 5 | 5 | 5 | 4 | 4 | 4 | 4 | 5 | 5 | 5 | 5 | 5 | 4 | 5 | 5 | 5 | 5 | 4 | 4.7 |
| I know who to turn to regarding health concerns or for counselling | 5 | 5 | 5 | 5 | 5 | 5 | 4 | 5 | 5 | 4 | 5 | 5 | 5 | 5 | 5 | 5 | 4 | 5 | 5 | 4 | 5 | 4.8 |
| **Decision regret**2 | | | | | | | | | | | | | | | | | | | | | | |
| I am glad that the Biobank contacted me regarding the genetic finding | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 4 | 5 | 5 | 5 | 5 | 3 | 5 | 4 | 5 | 4.8 |
| **6-month follow-up** | **Emotional Response**1 | | | | | | | | | | | | | | | | | | | | | | |
| I feel calm | NA | 3 | NA | 3 | 4 | NA | 3 | 3 | 4 | 3 | 4 | 4 | NA | 4 | 4 | NA | 3 | 3 | NA | NA | NA | 3.5 |
| I am tense | 2 | 2 | 1 | 2 | 2 | 1 | 2 | 1 | 1 | 1 | / | 2 | 1 | 1.5 |
| I feel upset | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | / | 2 | 1 | 1.7 |
| I am relaxed | 3 | 3 | 4 | 3 | 3 | 2 | 3 | 4 | 4 | 4 | / | 3 | 4 | 3.3 |
| I feel content | 4 | 3 | 3 | 1 | 3 | 2 | 3 | 3 | 4 | 4 | / | 2 | 3 | 2.9 |
| I am worried | 2 | 2 | 2 | 2 | 3 | 2 | 2 | 1 | 1 | 1 | / | 2 | 2 | 1.8 |
| **Coping and decision regret**2 | | | | | | | | | | | | | | | | | | | | | | |
| I am able to cope with having this condition in my family |  | 5 |  | 5 | 5 |  | 5 | 4 | 5 | 5 | 5 | 5 |  | 5 | 5 |  | 4 | 5 |  |  |  | 4.8 |
| It was the right decision | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 4 | 4 | 4.8 |
| I regret the choice that was made | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | / | 2 | 2 | 1.3 |
| I would go for the same choice if I had to do it over again | 5 | 5 | 5 | 5 | 5 | 4 | 5 | 5 | 5 | 5 | / | 5 | 4 | 4.8 |
| The choice did me a lot of harm | 1 | 1 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | / | 2 | 1 | 1.3 |
| The decision was a wise one | 5 | 4 | 5 | 5 | 4 | 5 | 5 | 5 | 5 | 5 | / | 4 | 4 | 4.7 |
| **Perceived impact**2 | | | | | | | | | | | | | | | | | | | | | | |
| I now have better access to health care / specialists |  | 3 |  | 2 | 2 |  | 5 | 2 | 1 | 5 | 3 | 5 |  | 5 | 5 |  | 3 | 4 |  |  |  | 3.5 |
| I feel that my treatment and/or condition has improved | 4 | 4 | 1 | 2 | 3 | 3 | 4 | 3 | 3 | 3 | 3 | 1 | 3 | 2.8 |
| The information received has somehow changed my life | 5 | 5 | 5 | 5 | 4 | 5 | 5 | 5 | 5 | 5 | 5 | 4 | 5 | 4.8 |

1 Responses given on a four-point scale: 4, very much; 3, moderately; 2, somewhat; 1, not at all; /, response left blank.

2 Responses given on a five-point Likert scale: 5, agree; 4, slightly agree; 3, difficult to say; 2, slightly disagree; 1, disagree; /, response left blank.

**Table S5. Breast cancer population screening vs. identification of high-risk individuals: criteria for further risk evaluation**

|  |  |  |
| --- | --- | --- |
|  | **National screening program** | **High risk individuals** |
| **Target-group** | 50-69 year old women with health insurance and no breast cancer at age 45–50 years; invitation every 2 years | An individual at any age with a known pathogenic/likely pathogenic variant in a cancer susceptibility gene within the family |
| **Counselling** | N/A | Counselling by medical geneticist |
| **Management and surveillance** | Breast awareness at age 20 years, breast self-exam every month | Breast awareness at age 18y, breast self-exam every month |
| At age ≥40 clinical breast exam once a year with gynecologist examination | Clinical breast exam, every 6-12 months breast MRI (starting at 25y) and breast mammogram (starting at 30y) |
| N/A | Every 6 months gynecologic checkup, transvaginal ultrasound, serum C1-125 and H4 tumor markers screening (starting at age 35y) |
| Follow-up by oncologist every 6 months |
| Discuss option of risk-reducing mastectomy |
| Discuss options for risk-reducing salpingo-oophorectomy when ≥35y |
| PSA analysis starting ≥ 50 y old men; ≥45 when at least 1 prostate cancer in the family | Prostate cancer screening for BRCA2 carriers starting at age 45y and clinical breast exam, every 12 months, starting at age 35y. Consider prostate cancer screening for BRCA1 carriers (considering family history) |
| **Relatives** | N/A | Recommendation for genetic counselling and consideration of genetic testing for close relatives |